Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EXOZ
Strong SellSinkereXoZymes, Inc. · Healthcare · United States · $67M · Avg Vol: $32K/d
2
StockRankGet insider-trade alerts
Q
19
V
22
M
19
P/E (TTM)
—
ROE
-187.2%
D/E
0.3x
Dividend %
—
COMPANY DESCRIPTION
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — |
| EPS | -0.17 | -0.25 | -0.89 | -1.09 | — | -1.20 |
| Shares | 8.1M | 8.1M | 8.4M | 8.4M | +3.4% | 9.3M |
| Debt | 0.6M | 1.6M | 1.4M | 1.2M | 26.9% | 1.1M |
| Equity | 1.4M | -0.4M | 10.4M | 3.4M | 35.3% | — |
| Op CF | -1.3M | -1.2M | -8.5M | -6.5M | — | -7.0M |
| Inv CF | -87.2K | -0.3M | -0.4M | -0.2M | — | — |
| Fin CF | 1.4M | 1.0M | 18.5M | -27.7K | — | — |
Loading 1Y...
PRICE (1Y)+34.1%
SMA 50SMA 200
Close
$6.17
RSI (14)
35.3
52W High
$18.40
From 52W High
0.3%
SCORE BREAKDOWN
Quality
19
ROIC
-220.6%2.3
ROE
-187.2%4.7
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-111.7%1.8
Piotroski
12.4
Int. Cover
—N/A
D/E Ratio
0.30x41.1
Current Ratio
3.81x64.0
Value
22
P/E (TTM)
—N/A
EV/EBITDA
-5.7x25.0
P/FCF
—N/A
P/B
17.4x6.5
P/S
—N/A
Div Yield
—N/A
Momentum
19
52W High %
34%9.3
RS 6M
-28%30.8
SMA 50/200
0.68x6.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$67M
P/E (Forward)
—
Gross Margin
0.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EXOZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EXOZ | eXoZymes, Inc.(you) | $67M | 2 | Strong Sell |
| RNTX | Rein Therapeutics Inc. | $66M | 2 | Strong Sell |
| IBIO | iBio, Inc. | $68M | 3 | Strong Sell |
| ESLA | Estrella Immunopharma, Inc. | $62M | 1 | Strong Sell |
| ELTX | Elicio Therapeutics, Inc. | $75M | 2 | Strong Sell |
| 2257.HK | Sirnaomics Ltd. | $55M | 1 | Strong Sell |
| FLNA | Filana Therapeutics, Inc. | $58M | 4 | Strong Sell |
| GOSS | Gossamer Bio, Inc. | $83M | 2 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%